A Catalyst for ​Change in the London Investment Landscape
​
London Growth Capital
Capital and investment opportunities are constantly evolving. What endures is the expertise required to identify value where others do not.
London Growth Capital's strategy is to offer differentiated long-term investment opportunities which will include the launch of our first two Long Term Asset Funds, designed to deliver lasting impact and attractive long-term performance through direct investing, thematic expertise and disciplined execution.
​
Our Healthspan Growth Property Fund and Life Sciences Growth Fund are intended to provide institutions, sovereign wealth funds and pension investors with access to distinctive opportunities across private and listed securities, supported by high transparency, specialist domain expertise, and a robust AIFMD-led governance and reporting framework.
​
​
________________________________
Innovation
Investment Management,
Wealth Management, Corporate Advisory
Our Funds 01
Life Sciences
Growth
Fund
Our Funds 02
Healthspan Growth Property
Fund
Website Disclaimer:
London Growth Capital Limited: is authorised and regulated by the Financial Conduct Authority (FRN 505249). Registered in England and Wales under company number 06649842. Registered office: 17 Hanover Square, Mayfair, London, W1S 1BN.
​
Telephone: +44 203 883 7810 | Email: admin@londongrowthcapital.com
​
The information on this website is provided for informational purposes only and does not constitute investment advice, an offer, or solicitation to purchase or sell any security or financial instrument. Any fund, sub-fund or strategy referenced is under development and subject to final documentation and any relevant regulatory authorisations. London Growth Capital Limited accepts no responsibility for any loss or damage arising from reliance on information contained on this site. Users should seek independent professional advice before making investment decisions. The contents of this website are intended for professional investors and eligible counterparties as defined by the Financial Conduct Authority and are not directed at retail investors.